AXA 41.520 € (+0,24 %) SOITEC 159.950 € (+4,95 %) 
ING GROEP N.V. 29.630 € (+0,70 %) HERMES INTL 1 283.000 € (+1,62 %) LVMH 380.000 € (-0,24 %) TOOSLA 0.000 € (-33,33 %) BE SEMICONDUCTOR 179.450 € (-0,25 %) CRCAM TOURAINE CCI 112.000 € (+2,56 %) 
DSM FIRMENICH AG 100.650 € (+2,81 %) LECTRA 20.850 € (+1,96 %) EUTELSAT COMMUNIC. 1.380 € (-1,85 %) AIRBUS 187.800 € (+0,29 %) CHRISTIAN DIOR 413.000 € (-0,48 %) ASR NEDERLAND 71.480 € (+0,22 %) SAFRAN 316.200 € (+1,74 %) ABIVAX 79.000 € (+2,46 %) 2CRSI 24.800 € (+5,80 %) VEOLIA ENVIRON. 31.090 € (+0,65 %) AUBAY 49.700 € (+2,47 %) ASML HOLDING 1 601.600 € (-1,78 %) MEDINCELL 29.060 € (+16,89 %) TIKEHAU CAPITAL 16.000 € (+2,70 %) ENGIE 22.750 € (+0,18 %) VOPAK 51.100 € (-0,10 %) RIBER 8.100 € (-3,46 %) UMG 14.900 € (+1,50 %) ABN AMRO BANK N.V. 40.450 € (+1,51 %) ALSTOM 15.600 € (-1,14 %) FASTNED 43.450 € (+2,36 %) MAGNUM 15.358 € (-0,60 %) TOTALENERGIES 78.530 € (+1,22 %) INFOTEL 38.000 € (+2,15 %) ADP 103.700 € (+1,57 %) PHILIPS KON 21.780 € (+1,40 %) PERRIER (GERARD) 72.200 € (+0,28 %) 
UNILEVER 55.300 € (+1,24 %) SHELL PLC 45.035 € (+0,64 %) EURONEXT 163.600 € (+1,18 %) ELIS 21.260 € (+0,76 %) ADUX 1.000 € (-1,96 %) MERCIALYS 9.460 € (0,00 %) ADYEN 886.100 € (+2,84 %) BOUYGUES 40.300 € (-0,81 %) 
ARCELORMITTAL SA 57.280 € (+5,64 %) FONCIERE INEA 31.100 € (+0,32 %) BOLLORE 3.668 € (+0,55 %) WOLTERS KLUWER 75.000 € (+4,49 %) CEGEDIM 10.700 € (-0,56 %) TELEPERFORMANCE 71.800 € (+2,63 %) GL EVENTS 24.300 € (+2,75 %) SCHNEIDER ELECTRIC 266.400 € (+2,03 %) SERGEFERRARI GROUP 5.540 € (-0,36 %) BIOMERIEUX 83.200 € (+3,48 %) ASM INTERNATIONAL 883.600 € (-1,65 %) EMEIS 10.050 € (+1,67 %) CLARIANE 3.322 € (+2,72 %) GROUPE SFPI 1.730 € (-0,57 %) HIGH CO 3.485 € (+1,90 %) REXEL 34.110 € (+2,34 %) LUMIBIRD 22.500 € (+2,74 %) |
10/01/2023 12:10
EQS-Adhoc: BRAIN Biotech AG: prioritizing development of therapeutic applications of the Akribion Genomics technology platform (genome-editing)EQS-Ad-hoc: BRAIN Biotech AG / Key word(s): Strategic Company Decision BRAIN Biotech AG: prioritizing development of therapeutic applications of the Akribion Genomics technology platform (genome-editing) Zwingenberg, Germany BRAIN Biotech AG (“BRAIN”) announces that at the Supervisory Board meeting held today, the Executive Management Board of the company with the consent of the Supervisory Board decided to prioritize the development of therapeutic applications of the genome editing activities bundled under the brand name Akribion Genomics, this includes potential applications in oncology. The mode of action of the BRAIN nucleases selected for this purpose allows both the targeted enrichment and depletion by selective destruction of cells. This may open up fields of application in the area of therapeutics with considerable market potential. Akribion Genomics is currently establishing a partner network for the further development of this platform technology in therapeutic, diagnostic and industrial fields of application.
Information and Explanation of the Issuer to this announcement: About BRAIN Biotech BRAIN Biotech AG is a leading European industrial biotechnology specialist with a focus on nutrition, health and the environment. As a technology and solutions provider the company supports the biologization of industries with bio-based products and processes. From contract R&D with industrial partners to advancing own disruptive incubator projects and customized enzyme products, BRAIN’s broad cutting-edge biotech expertise and its agile teams are key to success. - BRAIN Biotech AG, Germany, is the parent company of the international BRAIN Group, distributing specialty B2B products like enzymes or bioactive natural products. The BRAIN Group has its own fermentation or production facilities in Continental Europe, UK and the US, which together with the associated biotechnological solution competency complete the value chain within the group. - As a Participant of the United Nations Global Compact, BRAIN Biotech AG is committed to aligning strategies and operations with universal principles on human rights, labour, environment and anti-corruption and to actively advance common societal goals. BRAIN Biotech´s products and services target at least five of the UN SDGs directly. - Since its IPO in 2016, BRAIN Biotech AG is listed in the Prime Standard of the Frankfurt Stock Exchange (ISIN DE0005203947 / WKN 520394). 10-Jan-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
1530979 10-Jan-2023 CET/CEST Source : Webdisclosure.com |
||||||||||||||||||||||||||||||||
Cotations différées d'au moins 15 minutes (Paris, Amsterdam, Bruxelles, Lisbonne).
Cotations à la clôture (Francfort, New-York, Londres, Zurich).
Flux de cotations : Euronext (Places Euronext et Cours des Devises).
Bourse : technologie Cote Boursière